Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Myeloproliferative Disorders 2Blast Crisis 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × fedratinib × Clear all
NCT05127174 2025-12-04

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Terminated
12 enrolled
Myeloid

Myeloproliferative Disorders

NCT05524857 2024-04-23

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Columbia University

Phase 1 Terminated
2 enrolled
Myeloid

Blast Crisis, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡